Amerinet Members Now Have Access to Savings on Early Breast Cancer Detection NASHUA, N.H., Oct. 27 /PRNewswire-FirstCall/ -- iCAD(R), Inc. (NASDAQ: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, and Amerinet, a leading US health care group purchasing organization, today announced an agreement that enables Amerinet members to purchase iCAD products at preferred pricing. The non-exclusive agreement includes all iCAD film-based mammographic CAD solutions and the new TotalLook(TM) system, which acquires prior film mammograms at full image fidelity for use in comparative reading with digital mammography. Preferred pricing is available to Amerinet's 1,900 plus hospitals and 1,421 ambulatory surgery centers. The Amerinet-iCAD Purchasing Agreement becomes effective November 1, 2005 and extends through October 31, 2008. Amerinet is one of the most innovative and effective healthcare group purchasing organizations in the United States, leading the industry in flexibility with a commitment to providing supplier choice for its members. Amerinet's national network of companies -- Amerinet Central, Intermountain Health Care and Vector -- has set a standard for customer service for nearly two decades. An increasing number of radiologists use computer-aided detection as a "second pair of eyes" when reading a mammogram. iCAD has the potential to detect findings that might otherwise be overlooked during the review process, thus increasing cancer detection. CAD technology is especially effective in identifying calcifications, some of which can be cancerous. Clinical trials demonstrated that use of the SecondLook systems could result in earlier detection of up to 25% of the cancers an average of 15 months earlier for those patients currently detected with screening mammography. About iCAD, Inc. iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan's Growth Strategy Leadership award, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over eleven hundred women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com/. About Amerinet, Inc. Amerinet is one of the most innovative and effective health care group purchasing organizations in the United States, partnering with members to improve their operating margins. Amerinet leads the industry in flexibility with a commitment to providing supplier choice for its members. Amerinet's national network of companies has set the standard for customer service for nearly two decades. More than 1,900 hospitals and 33,000 non-acute care facilities find cost savings and value-added services through Amerinet's comprehensive contract portfolio. Members trust Amerinet to deliver proactive information and integrity. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "anticipate," "likely," and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. iCAD and Second Look are registered trademarks of iCAD, Inc. For iCAD investor relations, contact Kevin McGrath of Cameron Associates at +1 212 245 4577 or via email at . For all other iCAD inquires, contact Monica Pandolfi of SHIFT Communications at +1 617 681 1235 or via email at . DATASOURCE: iCAD, Inc. CONTACT: Kevin McGrath of Cameron Associates for iCAD, +1-212-245-4577, ; or Monica Pandolfi of SHIFT Communications for iCAD, +1-617-681-1235, Web site: http://www.icadmed.com/

Copyright